Impact of the COVID-19 Outbreak on Adjuvant Chemotherapy for Patients with Stage II or III Colon Cancer: Experiences from a Multicentre Clinical Trial in China

L. Sun; Y. Xu; T. Zhang; Y. Yang

doi:10.3747/co.27.6529

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Commentary

1 June 2020

Impact of the COVID-19 Outbreak on Adjuvant Chemotherapy for Patients with Stage II or III Colon Cancer: Experiences from a Multicentre Clinical Trial in China

and

Oncology Department, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Author to whom correspondence should be addressed.

Curr. Oncol.2020, 27(3), 159-162;https://doi.org/10.3747/co.27.6529

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Since January 2020, the outbreak of the novel coronavirus disease designated covid-19 by the World Health Organization, a human-to-human contagious viral pneumonia that began in 2019, has been extensively influencing daily life in China[...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Tumour Response 3 Months after Neoadjuvant Single-Fraction Radiotherapy for Low-Risk Breast Cancer

Preparing for the Renaissance: Treating Breast Cancer during the COVID-19 Pandemic and Planning for a Safe Re-Emergence to Routine Surgical Care within a Universal Health Care System